Home

Home

article image

Screening

It’s time to examine the quality of diagnostic reporting

Switzerland - European experts presented and debates that controversial topic – breast cancer screening programmes – during a September symposium organised by Carestream Health.

Almost all EU countries have established screening programmes, which have lead to an impressive increase in early detection rates compared with those before these programmes began. The conclusion is that the breast cancer mortality rate – the most common cause of death in women – could be decreased continuously. However, the number of late detected carcinomas is still considerable.
Henny Rijken and Prof. Roland Holland, of the National Expert and Training Centre for Breast Cancer Screening, in Nijmegan University Hospital, the Netherlands, focused on the role ‘quality of diagnostic reporting’ plays in a successful screening programme. ‘The Netherlands’ screening programme is well-established nationwide,’ Henny Rijken said. ‘We now have to look behind the facts and figures of our current statistics and ask how we can improve the results. That’s why we examined the differences in the quality of diagnostic reporting. In the Netherlands, due to very strict rules and guidelines, the technical equipment everywhere is based on the same foundation. However, of course there are differences in the reporting quality – for example concerning recall rates that, in general, can be said to be low. In our opinion, one reason for missing a carcinoma at an early stage could be that the number of women invited for further examinations – which could clarify any uncertainty – is too low. This can be seen from figures coming from areas with an above average recall rate that also have above average detection rates. On the other hand, there are areas where the recall rate is equally high, but with a less optimal detection rate. In that case the knowledge and experience of the radiologist might play an important role for screening success,’ he pointed out.
The statistics presented by the Netherlands duo prompted serious discussions about ways to further improve screening quality and therefore save more lives.

This article was published on 10/30/2007

Search

 

Service

Company News

Carestream: technical infrastructure for EU funded R-bay project

Carestream Health is a major technical infrastructure provider to the EU-funded R-Bay validation project, which aims to address the uneven spread of radiologists across member states. CARESTREAM Radiology and Information Management Solutions are driving the initial test platform for the project by facilitating remote reporting of images from hospitals in Denmark, Finland and Czech Republic by clinical providers in Estonia, Lithuania and the Netherlands.

Insulin in oral capsules

At the international congress on diabetes in September, Oramed Pharmaceuticals, Inc. introduced its oral insulin capsules that might in the future replace injections patients currently have to face. Last week Oramed announced the agreement with ETI Karle Clinical Pvt. Ltd. to conduct phase 2B clinical trials for its oral insulin capsules.

Products redesigned to help patients simplify life with diabetes

Bayer HealthCare Diabetes Care unveiled the new
CONTOUR® blood glucose meter with enhanced testing features at the 44th Annual Meeting of the European Association for the Study of Diabetes in Rome, Italy.